Q4 revenue consensus $18.29M.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT:
- ADC Therapeutics Reports Promising LOTIS-7 Trial Results
- Promising LOTIS-7 Trial Results Reinforce Buy Rating for ADC Therapeutics
- ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma
- ADC Therapeutics: Strong Financials and Upcoming Trial Catalysts Support Buy Rating
- ADC Therapeutics Reports Q3 2025 Financial Results